NEJM Group

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

March 28th, 2014

ACC.14 Headquarters

wpengine

CardioExchange is dedicated to bringing you the latest from ACC.14. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think!

News:

  • No Benefit Found in First Real Test of Renal Denervation
  • Survival Advantage for TAVR Over Surgery in High-Risk Patients
  • First TAVR Comparison Trial Favors Sapien XT Over CoreValve
  • MADIT-CRT Long-Term Follow-Up Shows Survival Benefit with CRT-D
  • High-Sensitivity Troponin Test Could Identify Low-Risk Chest Pain Patients in the ED
  • Aspirin and Clonidine Fail to Help Surgery Patients
  • Novartis Trial Was Stopped Early Because of a Significant Drop in Cardiovascular Mortality

Analysis:

  • Negative Findings on Renal Denervation for Hypertension: Sweet SYMPLICITY?
  • TAVR: Are You Impressed Now?
  • Long-Term Follow-Up from MADIT-CRT: Guideline Implications
  • Are We Equipped to Make a CHOICE Between TAVR Devices?

Follow our Fellows:

  • Changing My Priorities for ACC.14
  • Ideals Lost, But Not Stolen
  • Are Digital Conferences the Way of the Future?
  • Taking Patient-Centerdness to the Next Level at ACC.14
  • Stage Set for Phase IV Trials of PCSK9 Inhibition
  • Master of all Trades

Categories: General


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

  • Search the Archive

  • Archives by Date

  • RSS NEJM — Recent Cardiology Articles

    • Digital Twin–Guided Ablation for Ventricular Tachycardia April 2, 2026
      In a 10-patient feasibility study, heart digital twins were used to guide VT ablation. Afterward, VT was noninducible in all patients; at a mean follow-up of 13 months, 8 patients were free of recurrence, without drug therapy.
    • Discontinuation of Beta-Blocker Therapy after Myocardial Infarction April 2, 2026
      Among patients with a preserved ejection fraction at least 1 year after myocardial infarction, stopping beta-blockers was noninferior to continuing therapy with respect to major clinical outcomes.
    • Simulating and Teaching the Physiology of Pulsus Paradoxus April 2, 2026
      In a simulation involving 15 healthy trainees, slowing respiration to 10 seconds per breath produced pulsus measurements exceeding 20 mm Hg, enabling improved teaching simulation and understanding of underlying physiology.
    • The Age Illusion — Limitations of Chronologic Age in Medicine April 2, 2026
      Chronologic age plays an outsized role in various aspects of medicine. Yet people of the same age can differ dramatically when it comes to aging-related risk factors.
    • Left Atrial Appendage Closure — Another Overused Method in Cardiology? April 2, 2026
      Untreated atrial fibrillation carries an approximately 3 to 5% annual risk of ischemic stroke. Long-term oral anticoagulation therapy decreases this risk to 1.7% with warfarin and to 1.5% with edoxaban, as shown in the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction...
  • Tag Cloud

    • ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
NEJM Group

Copyright © 2026 Massachusetts Medical Society. All rights reserved.

The content of this site is intended for health care professionals. Copyright | Terms | Privacy Policy |